by Mary Stuart
One of the hottest, fastest growing areas for device technology, interventional neurology, actually has at its roots cardiovascular medicine and pharmaceuticals, specifically the June 1996 approval of Genentech Inc. ...
The Tantalizing Market for Stroke Devices
A potentially enormous market without therapeutic options is attracting a lot of new technology developesr and venture capital to stroke. But the opportunity for clot-busting approaches is limited and getting enough patients for clinical trials is tough. In a market full of unknowns, one thing is certain: the ultimate goal of any stroke therapy is to avoid neurological deficit.
More from Archive
More from Medtech Insight
• By
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
• By
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
• By
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.